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A novel coronavirus called SARS-CoV-2 has caused the emergency release of the most 
well-known molecular assay, the CDC N1 RT-PCR assay, causing reports of poor analytical 
performance resulting in false-negative results (20, 26), and inconsistent testing kits received 
(23, 32). An immediate and dire need for a rapid and reliable SARS-CoV-2 testing workflow 
specifically designed for a university setting is the purpose this project is aiming and intended to 
fulfill. The workflow design uses a less invasive saliva sample for rapid screening using 
colorimetric RT-LAMP detection of three SARS-CoV-2 gene regions for Orf1ab, envelope, and 
nucleocapsid. Purified SARS-CoV-2 genomic RNA is spiked into Proteinase K and heat-treated 
saliva from a SARS-CoV-2 negative donor to simulate a positive donor sample used to 
characterize and optimize this workflow, detecting 200 copies of SARS-CoV-2 genomic RNA 
by all three gene targets. The utility of colorimetric RT-LAMP outperformed the CDC N1 RT-
PCR assay in turn-around-time and analytical performance. When applied to a small surveillance 
study, five out of 47 asymptomatic saliva donors had (September 2020) detectable SARS-CoV-2 
genetic material, resulting in a 10% positivity rate, with the campus dashboard reporting <1%. 
With a higher SARS-CoV-2 prevalence rate detectable through this workflow than what the 
university was previously finding using the suboptimal RT-PCR testing, the surveillance shut 
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INTRODUCTION AND LITERATURE REVIEW 
 
 
This Thesis follows the format specified by the 7th Edition of the Publication manual of 
the American Psychological Association. Severe Acute Respiratory Syndrome Coronavirus 2, 
SARS-CoV-2, and COVID-19 are all used to describe a novel virus discovered in late 2019 in 
Wuhan, China, that has been responsible for the continued accumulation of more than 3 million 
deaths worldwide (29). The origins of this virus speculated to begin in bat or pangolin species, 
subsequently acquiring mutations or undergoing recombination events allowing for zoonotic 
transmission to humans (2). These have been the suggested models due to high sequence 
homology between the S gene of SARS-CoV-2 and the genes of coronaviruses specifically found 
in bat or pangolin hosts (2).      
COVID-19 disease harbors many symptoms in an infected person or can cause an 
asymptomatic carrier-like infection (6). Symptoms can include but are not limited to fever, chills, 
cough, fatigue, or a characteristic loss of taste and smell, with symptom onset occurring 2-14 
days after initial infection (6). In severe cases, acute respiratory distress syndrome can develop, 
more commonly known as a cytokine storm, a highly erratic inflammatory response that can be 
lethal (22). Transmission of infection is through respiratory droplets created from an infected 
individual when sneezing, speaking, or coughing (5). The high-risk mortality group for this 
infection is anyone ≥60 years of age and anyone with underlying health conditions (5). 
SARS-CoV-2 is a spherical enveloped virus roughly 120 nm in diameter containing a 
positive-sense single-stranded RNA genome with an approximate size of 30,000 bases (15). The 
genomes' basic structure begins with a 5' CAP and 3' Poly-A-tail and is bound to nucleocapsid 
structural proteins producing a helical conformation (15). This virus belongs to 
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the Coronaviridae family and Betacoronavirus genus of viruses (9, 19). The genome size of 
viruses within this group includes giant viral RNA genomes cataloged to this date (9). 
The Betacoronavirus genus is genetically distinguished from the Alpha, Gamma, and Delta 
groups by a specific non-structural proteins’ gene size and sequence variation. In addition, Alpha 
and Betacoronaviruses infect mammalian hosts, Gammacoronaviruses infected avian hosts, 
and Deltacoronaviruses can infect both mammalian and avian hosts (9). Of the many different 
coronavirus species, the four common coronavirus species that infect human hosts are Human 
Coronavirus 229E, NL63, OC43E, and HKU1 (1).  
Once a SARS-CoV-2 viral particle is endocytosed, within a host cell, viral replication 
occurs through discontinuous transcription of 13-15 open reading frames, of which 12 are 
functional, resulting in the production of four structural proteins and 16 non-structural proteins 
(18). The four structural proteins include the spike protein, which mediates viral entry into host 
cells through spike protein and host angiotensin-converting enzyme 2, or ACE2, cell-surface 
receptor interaction (9, 21). Structural proteins are involved in new virion formation, virion 
release, host cell entry, and other vital functions in the viral lifecycle (21). The 16 non-structural 
proteins perform various roles involved in viral replication, survival, and host immune system 
evasion (18). In figure 1 below is a depiction of a cartoon image of a SARS-CoV-2 virion 
highlighting the four structural proteins nucleocapsid (b), spike (c), envelope (d), membrane (e), 







Figure 1 SARS-CoV-2 Virion, and Genome Organization. (A) SARS-CoV-2 structural proteins 
nucleocapsid (b), spike (c), envelope (d) and membrane (e) are identified along with the helical genomic 
RNA (a). (B) Genomic organization of identified SARS-CoV-2 genes with structural proteins in light 
gray.  
 
Asymptomatic carrier infections of COVID-19 disease bring a unique challenge to 
restricting viral spread throughout the community, as testing resources are being reserved for 
symptomatic cases in addition to individuals not knowing they are sick. Those asymptomatic 
carriers are likely not taking the appropriate quarantine measures and are unknowingly 
promoting community spread of the virus. Attention to these two factors is the key to developing 
a better strategy for managing this pandemic, as there would be a plan in place for symptomatic 
and asymptomatic infection transmission.  
December 31st, 2019, was the initial report of the first group of COVID19 cases in 
China, and March 11th, 2020, officially declared a pandemic by the World Health Organization 
(WHO) (28). The action taken by the FDA in response to the emerging global public health risk 
was the emergency release of a CDC developed Real-time Polymerase Chain Reaction (RT-





the detection of the SARS-CoV-2 nucleocapsid gene (16). In response to the ongoing pandemic, 
the FDA authorized the emergency release of the CDC developed RT-PCR assay, which 
provided a much-needed test for the diagnosis and monitoring of the novel SARS-CoV-2 virus. 
Despite the positive impact of the development of the test, its emergency release left potentially 
unresolved shortcomings of the analysis. Resolution of shortcomings occurs during a standard 
and necessary validation process required for all high-complexity testing that the FDA 
investigates to prevent inaccuracies in reporting.  
Real Time-Polymerase Chain Reaction (RT-PCR) utilizes the basic PCR principle in 
addition to real-time monitoring of amplification. Polymerase Chain Reaction, or PCR, utilizes 
three main stages in its methodology, denaturation, annealing, and extension (3). The first step of 
denaturation occurs at approximately 95°C breaking the hydrogen bonds between double-
stranded DNA, resulting in single strands. The second step of annealing is temperature-
dependent based on primer composition though generally occurring from 55-65°C. PCR uses 
primers are specially designed short oligonucleotide sequences 20-30 base pairs in length that 
bind to their desired region using Watson-Crick base pairing rules and provide a starting point 
for replication. The extension is the last stage of PCR occurring at 72°C allowing the Thermus 
aquaticus (Taq) DNA polymerase to extend off the primer's 3' end, creating a complimentary 
copy of the target. Taq polymerase creates phosphodiester bonds between two nucleotides by 
joining a 3' hydroxyl group of one nucleotide to a 5' phosphate group of another nucleotide base 
(3).  
This three-step process of denaturation, annealing, and extension occurs multiple times, 
commonly referred to as cycles (3). The real-time characteristic of RT-PCR is possible by 
utilizing signaling molecules or dyes, allowing for fluorescent detection to generate a graph 
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displaying the level of fluorescent intensity as the reaction occurs (3). Two critical pieces of 
information gathered from an RT-PCR amplification curve are the efficiency of the reaction and 
the Ct-value. Reaction efficiency is determined by the visual shape of the amplification curve, 
with a sigmoidal shape indicating optimal efficiency. The Ct-value is used to quantify genetic 
material within a sample, in which the Ct-value is the cycle at which the fluorescence crosses the 
threshold or base level of the fluorescent signal (24).  
Taqman probes are a common component used in RT-PCR molecular assays, which 
allow for fluorescent detection and enhance analytical specificity as this probe binds to its 
specific target region. A Taqman probe consists of a recognition sequence, a 3' quencher, and a 5' 
fluorophore. The fluorophore's fluorescence is quenched or absorbed by the quencher until it is 
cleaved off by the Taq polymerase enzyme during the extension step of the PCR cycle. This 
cleaving occurs after the probe binds to its complementary sequence, and the polymerase enzyme 
replicates through the probe using the 5’3' exonuclease activity, releasing the fluorophore 
allowing enough distance from the quencher signal to be detected (3).  
A nucleic acid dye commonly used in RT-PCR is SYBR Green 1, which binds non-
specifically to any double-stranded DNA molecule (3). During the extension step of PCR 
reaction, as polymerase creates the complementary sequence to the target sequence, SYBR 
Green 1 will bind to the double-strand as produced. The more double-stranded target generated, 
the more SYBR Green 1 will bind, and the more fluorescent signal will be generated (3).  
A post-amplification analysis in RT-PCR called a melt curve analysis utilizes SYBR 
Green 1 fluorescence for sequence identification (3). After all PCR cycles, the reactions are 
slowly heated to 95°C causing the denaturation or separation of double-stranded sequences. As 
the denaturation of sequences occurs, SYBR Green 1 will dissociate, and the fluorescent signal 
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will decrease. A sequence's melt temperature is when half of the target sequence becomes single-
stranded, which depends on the sequence composition. Cytosine and Guanine base pairs require 
more heat (energy) to separate than Adenine and Thymine due to more hydrogen bonds holding 
them together. This analysis generates curves or peaks from which an RT-PCR reaction 
specificity or use for sequence identity can be performed (3).  
A restriction digest is another laboratory technique used to aid in nucleic acid sequence 
identification using restriction enzymes that recognize a specific sequence and ‘cut’ the DNA 
backbone in a single strand or both strands at a specific site. The desired sample type for a 
restriction digest is a purified nucleic acid sample with a known sequence composition 
commonly produced using PCR. Using the SARS-CoV-2 nucleic acid sequence for analysis and 
the many available computer programs can determine which restriction enzymes will cut a 
sequence, how many cut sites are present. Once selected, the enzyme and nucleic acid sequence 
will be incubated at the appropriate temperature for digestion to occur, followed by inactivation 
of the enzyme if necessary. After a sequence has digestion, post-analysis of fragments using gel 
electrophoresis allows for sequence separation and identification based on length. 
The scientific community’s response to the emergency released CDC N1 assay generated 
reports of false-negative results from the suboptimal assays (20, 26) and variances found 
between testing kits (23, 32). These unoptimized tests have led to an increase in inaccurate 
results due to this emergency release and the requirement of additional work for laboratories 
performing these tests to optimize and resolve test shortcomings, which is yet another burden for 
already strained laboratory personnel. Novel virus detection can potentially create other 
shortcomings because of the lack of understanding of the virus and infection scientifically. As is 
the case with SARS-CoV-2, with studies reporting assay dependency on viral load development, 
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ultimately plays a role in discrepant and false-negative results (12, 14). These inaccuracies 
indicate an optimal testing window in which a certain amount of time must pass after initial 
infection, such that enough viral replication has occurred to be detectable using the desired 
testing methodology or specimen type.  
Among the many molecular techniques used in diagnostics, LAMP and RT-LAMP 
applications are prevalent in many different clinical research areas such as microbiology and 
oncology due to the desirable attributes previously mentioned. In the context of SARS-CoV-2 
application, LAMP primers have been previously designed and tested for targeting the 
nucleocapsid (31), envelope (30), and Orf1ab (13) genes generating comparable results to the 
designated gold standard, RT-PCR, increasing the potential of its application in COVID19 
diagnosis. In addition, studies have shown that in place of the traditional nasopharyngeal swab 
sample type, saliva is a promising sample alternative (8, 10, 11, 17), and evidence of a simple 
pre-treatment increases detection efficiency (17, 25). 
Loop-Mediated Isothermal Amplification (LAMP) is an isothermal strand displacement 
nucleic acid amplification methodology recently developed by Notomi et al. (19). In contrast to 
many other traditional amplification methods, LAMP amplifies a target sequence at a constant 
temperature of approximately 65°C. LAMP employs a Bacillus stearothermophilus (Bst) DNA 
polymerase enzyme with strand displacement capabilities and a minimum of four primers 
recognizing six specific regions of a sequence as seen below in figure 2A and 2B. An additional 
two primers, loop forward and loop back, can be added for increased specificity and reaction 
efficiency. The use of reverse transcriptase allows this assay to be used for RNA applications 
formally called RT-LAMP (19). In RT-LAMP reverse transcription of the RNA template into 
copy DNA is performed before amplification occurs. The advantages of this methodology are 
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that it can be performed without the use of expensive thermocyclers, only requiring a heat source 
that can provide a consistent output of 65°C. This isothermal capability is due to the strand 
displacement activity of the Bst DNA polymerase enzyme. The last example of an advantage of 
using LAMP is that the sample input can be purified nucleic acid or a crude sample lysate, which 

















End-point analysis of LAMP amplification includes many different methods, including 
colorimetric, turbidimetric, gel electrophoresis, and nucleic acid dyes (21). The colorimetric end-
point analysis evaluates the color change of an indicator dye called phenol red incorporated into 
the master mix. The change from pink to yellow is the result of a pH shift from basic to acidic. 
During amplification, Bst DNA polymerase releases a pyrophosphate and hydrogen ion from the 
A B 
Figure 2 LAMP Primer Binding Schematics. (A) 
Primer binding regions utilized by FIP, BIP, B3, F3, 
Loop forward, and Loop back primers and their 
relative locations within the target sequence. (B) 
LAMP process from initiation through formation of 
the starting dumbbell amplicon required for 
amplification.    
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addition of a dNTP resulting in acidification, causing this color change as a result of the 
subsequent pH shift (26).  
Turbidimetric LAMPs principle measures the amount of formed magnesium 
pyrophosphate byproducts produced during the amplification process when pyrophosphate and 
magnesium ions react (27). The more amplicons generated, the more byproducts released, 
increasing sample turbidity in the form of a white precipitate, which is measured utilizing a 
turbidimeter. A LAMP reaction of approximately 60 minutes can result in the expansion of up to 
109 amplicons of a targeted sequence. Samples used in LAMP reactions can be purified nucleic 
acids or crude sample lysates and are not subject to the interference of common PCR inhibitors 
such as heme found in blood (27).  
The initial aim of this project was to optimize a diagnostic workflow for asymptomatic 
SARS-CoV-2 surveillance using saliva samples and the CDC N1 RT-PCR assay to produce a 
test for campus-wide surveillance with a rapid turn-around-time. Due to the poor performance of 
the CDC N1 RT-PCR assay, an RT-LAMP design is successful in detecting three specific gene 
targets for SARS-CoV-2 and used for mass surveillance. 
Methods 
CDC N1 RT-PCR Assay Design 
Primer stocks used in RT-PCR assays purchased through Integrated DNA Technologies 
(IDT), and adequately reconstituted to 100 µM in IDTE buffer at 8.0 pH from IDT and stored at 
-20°C. Prior, RT-PCR complete primer sets for the CDC N1 assay made in a cold block to a 
concentration of 2, 4, and 6 µM for the combined forward and reverse primers, and 1.25, 2, or 





Figure 3 CDC N1 Primer and Probe Alignment to SARS-CoV-2 Nucleocapsid Genomic Sequence. 
CDC N1 RT-PCR forward and reverse primers shown in a red font, and Taqman probe shown in a blue 
font. Primers and probe anneal to their respective regions shown in larger black font within the template 
strands.  
  
Components of an RT-PCR reaction consist of 18 µL of complete LightCycler® 480 
RNA Master Hydrolysis Probes master mix and 2 µL of a nucleic acid sample while kept in a 
cold block and gently mixed by pipetting in the wells of Light Cycler 480 multiwell plate and 
covered using Light Cycler 480 sealing foil from Roche. RT-PCR analysis performed using a 
Roche Light Cycler 96 using the following parameters, reverse transcription at 63°C for 180 
seconds followed by denaturation at 95°C for 10 seconds, annealing 55°C for 10 seconds, 
extension at 72°C for 10 seconds, for 40 cycles using the FAM detection channel. Figure 3 
shows the primer alignment of the CDC N1 forward primer, reverse primer, and probe to the 
SARS-CoV-2 nucleocapsid gene creating a 72 base pair product. 
RT-LAMP Assay Design 
LAMP primers purchased through Integrated DNA Technologies (IDT) and properly 
reconstituted to 100 µM in sterile IDTE buffer at 8.0 pH from IDT and stored at -20°C. RT-
LAMP complete primer sets for nucleocapsid, envelope, and Orf1ab are made to a working 





Table 1 LAMP Complete Primer Mix Specifications. 
LAMP primer mixes 
LAMP primer Stock concentration Working concentration 
Final concentration 
(Per 25 µL Reaction) 
FIP 100 µM 16 µM 1.6 µM 
BIP 100 µM 16 µM 1.6 µM 
F3 100 µM 2 µM 0.2 µM 
B3 100 µM 2 µM 0.2 µM 
LB 100 µM 4 µM 0.4 µM 
LF (not in envelope set) 100 µM 4 µM 0.4 µM 
 
Primer alignment to the targeted SARS-CoV-2 gene sequences can be seen below for 
primer set Orf1ab, envelope, and nucleocapsid in figures 4, 5 and 6 respectively, along with the 
primer sequences shown in table 2. 
 
Figure 4 Orf1ab Primer Alignment to SARS-CoV-2 Genomic Sequence. RT-LAMP primers aligned 
to SARS-CoV-2 Orf1ab gene sequence.   
 
 
Figure 5 Envelope Primer Alignment to SARS-CoV-2 Genomic Sequence. RT-LAMP primers 






Figure 6 Nucleocapsid Primer Alignment to SARS-CoV-2 Genomic Sequence. RT-LAMP primers 
aligned to SARS-CoV-2 nucleocapsid gene sequence.   
 
Table 2 RT-LAMP Primer Sequences for Orf1ab, Envelope, and Nucleocapsid. 































RT-LAMP Colorimetric End-Point Analysis 
Components of a colorimetric RT-LAMP reaction can be found below in table 3 and 
consist of 20 µL of the LAMP complete master mix and 5 µL of nucleic acid sample and gently 
mixed by pipetting the mixture while in a cold block. Amplification of samples occurs by 
incubation for 40 minutes in a 65°C water bath and reaction inactivation by a 5-minute 
incubation in a 95°C water bath. Samples cooled at room temperature before color change 
interpretation. 
Table 3 Colorimetric RT-LAMP Complete Master Mix Components. 
 
RT-LAMP complete master mix components (Per Reaction) 
 
Component Volume (µL) 
NEB WarmStart Colorimetric LAMP 2X 
Master Mix (DNA & RNA) 12.5 
Complete primer mix 2.5 
Sterile molecular grade H2O 5.0 
Total volume 20.0  
 
RT-LAMP Turbidimetric End-point Analysis 
Components of a turbidimetric RT-LAMP reaction can be found below in table 4 and 
consist of 20 µL of the LAMP complete master mix, and 5 µL of nucleic acid sample and gently 
mixed by pipetting. Amplification is performed using an Eiken LA-500 Loopamp Turbidimeter 
using the SARS pre-programmed setting of amplification at 62.5°C for 45 minutes, and 







Table 4 Turbidimetric RT-LAMP Complete Master Mix Components.  
 
RT-LAMP complete master mix components (Per Reaction) 
 
Component Volume (µL) 
NEB WarmStart LAMP kit (DNA & 
RNA) 12.5 
Complete primer mix 2.5 
Sterile molecular grade H2O 5.0 
Total volume 20.0  
 
 
Enzyme Restriction Digest  
Restriction Digest Design  
Nucleic acids used in restriction digests were generated by first reverse transcription 
using 2 µM final concentration of LAMP primer B3, followed by LAMP F3 and B3 primers at a 
final concentration of 1 µM each and amplification using RT-PCR and the KAPA SYBR fast 
one-step kit with 20 µL complete master mix and 5 µL of nucleic acid. The annealing 
temperature used was 65°C with 40 total PCR cycles. Restriction enzymes Apol-HF, Hpal, and 
Nde1, were purchased from New England BioLabs (NEB) and stored at -20°C. The enzymes 
Apol-HF, Hpal, and Ndel, were used to digest the Orf1ab, envelope, and nucleocapsid RT-PCR 
amplicons. Below in figure 7 is a schematic of the enzyme digest of each target region. The 
components and volumes of the restriction digest reaction are listed below in table 5 and added 
in sterile PCR tubes kept in a cold block, with the last component addition being the restriction 
enzyme. Tubes were incubated for 1 hour at 37°C and inactivated at 80 or 95°C for 20 minutes. 





Table 5 Restriction Digest Reaction Components. 
Restriction digest reaction components 
Component Volume (µL) 
New England BioLabs Restriction enzyme 1.0 
New England BioLabs SmartCut Buffer 5.0 
Molecular grade H2O 34.0 
Nucleic Acid 10.0 




Figure 7 Restriction Digest Design. Enzyme Binding and Cut Sequence Specifications for Ndel, 
Hpal, and Apol-HF. Recognition sequence is shown in blue lettering, and cut sites are shown with red 
vertical lines. The expected fragments and sizes are identified at the bottom of the figure. 
 
Agarose Gel Electrophoresis  
Agarose gel electrophoresis is used to visualize nucleic acids using an ethidium bromide 
(EtBr) dye. Gels were produced by combining the appropriate amount of powdered agarose and 
volume of 1XTBE buffer into an Erlenmeyer flask. The mixture was heated in a microwave until 
the agarose has fully dissolved, followed by the addition of EtBr. The solution was left to cool 
until warm to the touch before pouring into a gel casting tray. Samples were prepared by combining 
15 µL of a nucleic acid sample with 3 µL of New England BioLabs (6X) no SDS purple loading 
dye. Ladders were composed of 1 µL of the appropriate DNA ladder, 1 µL New England BioLabs 
(6X) no SDS purple loading dye into 4 µL of molecular grade H2O. 15 µL of each sample, and 6 
µL of the ladder were loaded into their respective wells. Using a Bio-Rad Powerpac basic power 
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supply, gels were run at 100-120V in 1XTBE solution for approximately 1 hour to 30 minutes. 
Gels were imaged using a Bio-Rad ChemiDoc using the UV Ethidium Bromide setting. 
Samples 
 Donor Sample Collection 
Under IRB approval the inclusion criteria for each donor are to not be experiencing any 
COVID19 symptoms, and no eating or drinking for at least 30 minutes prior to sample 
collection. Prior to collection each donor and medical professional must have the appropriate 
PPE and clean hands using soap and water or alcohol-based hand sanitizer. With or without the 
assistance of the medical professional, the donor will collect approximately one to two milliliters 
of saliva into a uniquely identified screw-top sterile tube without touching the rim of the tube 
with their hands avoiding contamination. With the tube in one hand and the cap in the other, the 
donor with tightly screw the top on their collection tube and place it into a holding rack.  
Saliva Treatment 
Prior to sample collection a level two-biosafety cabinet, from now on referred to as a 
hood, is designated for strict COVID19 testing use. After proper saliva collection as described 
above, donned with the appropriate PPE the sample is placed in a previously disinfected hood. A 
1/10 dilution of saliva with molecular grade water is produced in a PCR tube followed with the 
addition of 13 µL of 20 mg/mL Proteinase K (PK) from Biovision. Tubes are incubated at 56°C 
in a hot water bath for 15 minutes, and inactivation of proteinase K follows with a 10-minute 
incubation in a 95°C water bath. This treated saliva is the sample material used for the following 
molecular applications, and is stored at room temperature or stored in an Eppendorf tube in a -





Contrived samples are produced by combining treated saliva from a donor who is 
negative for SARS-CoV-2 infection, and viral genetic material. The viral genetic material used is 
purified SARS-CoV-2 genomic RNA from ATCC (ATCC number: VR-1986D lot: 70040832). 
Contrived samples are stored at -80°C.  
Results 
CDC N1 RT-PCR Results 
Initially, the CDC N1 RT-PCR forward and reverse primers were validated for use as the 
surveillance assay to reduce the overall cost and was the first commercially available diagnostic 
assay for SARS-CoV-2. Using a Roche LightCycler 96 and a standard 200 nM final primer 
concentration per reaction using the CDC-recommended annealing temperature of 55.0°C, an 
experiment to assess the quality of testing utilizing only the primers to lower the overall cost of 
testing by excluding the probe. Figure 8 below shows the amplification curves and melt curve 
analysis of the experiment assessing the quality of the CDC N1 primers. The image on the left 
shows the amplification curves generated using 200 copies of purified SARS-CoV-2 genomic 
RNA (a), human genomic DNA (b), IDTE buffer for the no template control (c) and 
the Staphylococcus Epidermidis bacterial DNA control (d). The image on the right shows the 
melt curve analysis of the 200 copies of SARS-CoV-2 genomic RNA (a) and purified human 
genomic DNA (b). From these images, the primers can efficiently amplify SARS-CoV-2 
genomic RNA generating a single product indicated by the single peak in the melt curve 




Figure 8 Non-specific binding of CDC N1 RT-PCR Forward and Reverse Primer Using SYBR 
Green 1. Amplification of SARS-CoV-2 genomic RNA and human genomic DNA using CDC N1 RT-
PCR forward and reverse primers with detection using SYBR Green 1.  
  
To increase the assay specificity, the CDC N1 Taqman probe was incorporated to reduce 
human genomic DNA interference using simulated saliva samples. First, the recommended CDC 
N1 primers (500 nM) and Taqman probe (125 nM) with an annealing temperature of 55.0°C 
were used as the assay parameters. Shown in figure 9 below are the amplification curves for the 
positive control of 1,000 copies of SARS-CoV-2 genomic RNA (a), contrived sample containing 
500 copies of SARS-CoV-2 genomic RNA (b), contrived sample containing 1,000 copies of 
SARS-CoV-2 genomic RNA (c), contrived sample containing 200 copies of SARS-CoV-2 
genomic RNA (d), and the no-template control containing sterile IDTE buffer (e). Curves a, b, 
and c have Ct-values of 27.59, 34.15, and 33.97 respectively. Using the CDC recommendations, 
the reaction efficiency and Ct-values are not close to the expected values when using saliva 
samples. The reaction efficiency is visually assessed by looking at the shape of the amplification 
curves with a sigmoidal shape indicating an optimal reaction efficiency, which is not readily 
apparent in the data shown here. This poor reaction efficiency negatively impacts the detection 
ability of the assay seen specifically in curves b and c. These curves were generated using 500 
and 1,000 copies of purified SARS-CoV-2 genomic RNA, respectively, and should produce 
separate amplification curves due to their difference in nucleic acid concentration. Curves b and 
c do not display the expected separation by Ct-value difference of 3.3 based on their difference 
in nucleic acid input, indicating poor reaction efficiency. Steps to improve reaction efficiency 
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other than modifying the primer sequences include their final concentration, the reaction 
annealing temperature, and reagents to improve DNA polymerase performance. 
 
Figure 9 Poor Test Performance of CDC N1 RT-PCR Using CDC Recommended N1 Primer and 
Probe Concentrations. Following samples (a) Positive control is 1,000 copies of SARS-CoV-2 gRNA, 
(b) contrived sample of 500 copies gRNA, (c) contrived sample of 1,000 copies gRNA, (d) contrived 
sample of 200 copies gRNA, (e) no template control of IDTE buffer analyzed using CDC recommended 
N1 primer and probe concentrations. Recommended final concentration of 500 nM for each primer and 
125 nM for probe. Amplification curve for Negative control of saliva from a SARS-CoV-2 negative at 
absorbance threshold line. 
 
The initial attempt to optimize the CDC N1 assay used different primer and probe 
concentrations to remedy the poor reaction efficiency and poor detection capability produced 
when using the CDC recommended concentrations. Primers tested at a final concentration of 100 
nM, 200 nM, and 300 nM each, with a probe concentration at 200 nM and 250 nM producing six 
unique groups. Figure 10 below shows the amplification curves generated testing the six 
different groups utilizing the same input samples as in the initial experiment. The bolded curves 
(if present) in each graph indicate samples belonging to each group. The primer and probe 
concentrations tested were above and below the CDC recommended use, which, regardless of the 
modification, no improvement to the performance of the assay occurred. This analysis was 
determined using the same criteria using the shape of the amplification curve, and the Ct-values 






Figure 10 Failed Optimization for CDC N1 RT-PCR Primer and Probe Concentrations. Following 
concentrations tested using an annealing temperature of 55.0°C are (1) 2 µM primer, 2.0 µM probe, (2) 2 
µM primer, 2.5 µM, (3) 4 µM primer, 2.0 µM probe, (4) 4 µM primer, 2.5 µM probe, (5) 6 µM primer, 
2.0 µM, and (6) 6 µM primer, 2.5 µM probe. Samples analyzed include positive control 1,000 copies of 
purified SARS-CoV-2 gRNA, contrived samples containing 1,000, 500, and 200 copies of SARS-CoV-2 
gRNA, no template control of IDTE buffer, and a negative control of saliva from a SARS-CoV-2 negative 
donor. Bolded lines indicate samples analyzed using the respective concentrations.  
 
The first optimization attempt of primer and probe concentration modification had no 
positive effect on the assay, leading to the second optimization attempt, which was the alteration 
of the annealing temperature used in the RT-PCR cycles to enhance the efficiency of the primers. 
The annealing temperature was tested at 55.0, 57.6, 59.0, 60.3, 61.7, 62.9, 63.9, and 64.6°C 
using 200 nM of each primer and 200 nM of Taqman probe. The primer and probe 
concentrations were used because they produced the best reaction efficiency based on a visual 
analysis of the previous experiment in figure 10 and produce similar results to the CDC 
recommended concentrations. The samples used in this second optimization are the same as the 
initial experiment, which generated the graphs in figure 11 below. The change in annealing 
temperature from 55.0°C had no positive effect on the reaction efficiency indicated by the shape 
of the amplification curves and their associated Ct-values. As seen in the images below, the more 
the annealing temperature is increased, the more the assay's performance is negatively impacted. 
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The lack of improvement when modifying the annealing temperature indicates the necessity of a 
third approach to optimize this assay further. 
 
Figure 11 Failed Optimization of CDC N1 RT-PCR Primer and Probe Annealing Temperatures. 
RT-PCR analysis using 4 µM primer, 2.0 µM probe amplification with annealing temperature 55.0-
64.6°C. Bolded amplification lines indicate samples amplified for each respective annealing temperature. 
Positive control is 1,000 copies of SARS-CoV-2 gRNA. Contrived samples containing 1,000, 500, and 
200 copies of gRNA. No template control of IDTE buffer, and a negative control of saliva from a SARS-
CoV-2 negative donor.  
 
As in the first and second optimization attempts changing two different assay 
characteristics failed to improve the performance; the third and final attempt at optimizing the 
assay was the addition of 1 µL per reaction of the LightCycler® 480 RNA Master Hydrolysis 
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Probe kit enhancer. The manufacturer recommended the enhancer when targeted nucleic acid 
sequences are high in G/C content. This approach is evaluated because the targeted sequence of 
the CDC N1 primers has roughly 50% G/C content. The final concentrations for each primer are 
200 nM and 200 nM of the Taqman probe with the CDC recommended annealing temperature of 
55.0°C. Figure 12 below shows the graph generated when using these parameters in addition to 
the enhancer reagent. Shown here are the amplification curves for the positive control of 1,000 
copies of SARS-CoV-2 genomic RNA (a), contrived sample containing 500 copies of SARS-
CoV-2 genomic RNA (b), contrived sample containing 1,000 copies of SARS-CoV-2 genomic 
RNA (c), contrived sample containing 200 copies of SARS-CoV-2 genomic RNA (d), and the 
no-template control containing sterile IDTE buffer (e). Respectively, the Ct-values for curves a-d 
are 27.73, 35.99, 35.25, and 39.39. The amplification curve shape and individual Ct-values 
generated show no significant improvement compared to data shown in figures 9-11, even with 
the addition of the reaction enhancer. The enhancer composition isn’t specified by the 
manufacturer but suspected to be Betaine or DMSO which increase DNA polymerase efficiency 






Figure 12 Failed Optimization of CDC N1 RT-PCR With Enhancer Reagent. RT-PCR analysis using 
4 µM primer, 2 µM probe with amplification annealing temperature at 55.0°C. Samples are (a) Positive 
control is 1,000 copies of SARS-CoV-2 gRNA, (b) contrived sample of 500 copies gRNA, (c) contrived 
sample of 1,000 copies gRNA, (d) contrived sample of 200 copies gRNA, (e) no template control of 
IDTE buffer and negative control of saliva from a SARS-CoV-2 negative donor. Each sample 
supplemented with 1 µL enhancer. 
 
Collectively, analysis using a Roche Light Cycler 96 and the LightCycler® 480 RNA 
Master Hydrolysis Probe kit this data shows that the CDC N1 RT-PCR assay cannot be further 
optimized by the adjustment of primer or probe concentrations, annealing temperature, or the use 
of a reaction enhancer when testing saliva samples. The assay cannot detect ≤ 200 copies of 
SARS-CoV-2 gRNA in contrived samples, and samples containing 500-1,000 copies generate 
Ct-values non-representative of their nucleic acid concentration differences. This evidence 
suggests that the CDC N1 primers are not compatible with saliva samples containing human 
genomic DNA, which amplify with poor reaction efficiency, negatively affecting the assay's 
performance. 
RT-LAMP Colorimetric Results 
The failure of the CDC N1 RT-PCR assay in producing robust results using saliva 
samples, and the failed attempts at optimization led to the investigation and development of an 
alternative assay design using RT-LAMP and independently developed and studied RT-LAMP 
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primers for Orf1ab by Lamb et al. (13), envelope by Yang et al. (30), and the nucleocapsid by 
Zhang et al. (31). Each primer set had performance evaluation using purified SARS-CoV-2 
genomic RNA along with the limit of detection that was determined using the colorimetric end-
point analysis. To determine the performance of the individual primer sets, each used different 
testing amounts of SARS-CoV-2 genomic RNA, performed in triplicate ranging from 2.5 copies 
per reaction to 200 copies per reaction. Figure 13 shows the colorimetric results for each primer 
set, with a pink color indicating no amplification and yellow indicating amplification occurred. 
Column 1 contains IDTE buffer as the no-template control, column 2 contains the negative 
control of saliva from a negative SARS-CoV-2 donor, and column 3 has the positive control of 
400 copies per reaction SARS-CoV-2 genomic RNA. The colorimetric results from this 
experiment show that all three primer sets can successfully detect SARS-CoV-2 gRNA, the 
envelope primer set offers the most significant sensitivity, and the lowest amount of genomic 
RNA per reaction that was detected in each triplicate by all three primer sets was 50 copies per 
reaction. 
 
Figure 13 Colorimetric RT-LAMP of SARS-CoV-2 gRNA Limit of Detection. Colorimetric 
interpretation after incubation for 40 minutes at 65.0°C and inactivated at 95.0°C for 5 minutes. Red font 
indicating limit of detection. Samples include IDTE buffer for non-template control, saliva from SARS-
CoV-2 negative donor for negative control, 400 copies of SARS-CoV-2 gRNA as positive control, and 
purified SARS-CoV-2 genomic RNA at concentrations from 2.5 copies – 200 copies reaction. 




To confirm the previous colorimetric results and determine the reproducibility of the 
primers, repeat colorimetric RT-LAMP analysis using a similar setup testing SARS-CoV-2 
gRNA amounts from 2.5 copies per reaction to 100 copies per reaction. Figure 14 below shows 
the repeat experiment which generated similar colorimetric results shown in figure 13. Columns 
one through three contain the same control material as previously mentioned. Based on the 
reproducibility of the RT-LAMP colorimetric end-point analysis, 50 copies per reaction can be 
considered the limit of detection for this study as 100% of the samples (18/18) reliably generated 
a robust positive color change while containing the lowest amount of genomic RNA. 
 
Figure 14 Colorimetric RT-LAMP of SARS-CoV-2 gRNA Limit of Detection Confirmation. 
Colorimetric interpretation after incubation for 40 minutes at 65.0°C and inactivated at 95.0°C for 5 
minutes. Red font indicating limit of detection. Samples include IDTE buffer for non-template control, 
saliva from SARS-CoV-2 negative donor for negative control, 400 copies of SARS-CoV-2 gRNA as 
positive control, and purified SARS-CoV-2 genomic RNA at concentrations from 2.5 copies – 100 copies 
reaction. Photographed using cell phone camera. 
 
Knowing that colorimetric RT-LAMP can reliably detect 50 copies per reaction of 
purified gRNA, can these primers be used to detect SARS-CoV-2 gRNA in saliva samples? If 
present PCR inhibitors in saliva do not inhibit detection, it is speculated that using contrived 
SARS-CoV-2 saliva samples will likely have a higher limit of detection as the matrix of the 
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sample increases, so does the detection limit of an essay. To determine the reliability of the 
LAMP primers for clinical samples, contrived samples are assayed and composed of SARS-
CoV-2 using treated saliva from a SARS-CoV-2 negative donor. The appropriate amount of 
ATCC purified viral RNA to achieve samples generating 50 copies per reaction to 250 copies per 
reaction. Figure 15 shows the first application of contrived samples using the colorimetric assay 
yielding the results below. Column 1 contains IDTE buffer as the no-template control, column 2 
is the negative control containing saliva from a negative SARS-CoV-2 donor, and column 3 is 
the positive control with 200 copies per reaction SARS-CoV-2 genomic RNA. The results 
obtained show that saliva can be successfully used for SARS-CoV-2 detection using RT-LAMP 
despite the difficulties associated with using saliva in molecular techniques. As expected, 
introducing saliva as the sample matrix did negatively impact the assay's sensitivity compared to 
using purified SARS-CoV-2 genomic RNA, but by the order of magnitude expected. 
 
Figure 15 Colorimetric RT-LAMP of SARS-CoV-2 Contrived Samples Limit of Detection. 
Colorimetric interpretation after incubation for 40 minutes at 65.0°C and inactivated at 95.0°C for 5 
minutes. Red font indicating limit of detection. Samples include IDTE buffer for non-template control, 
saliva from SARS-CoV-2 negative donor for negative control, 200 copies of SARS-CoV-2 gRNA as 
positive control, and contrived samples containing SARS-CoV-2 genomic RNA at concentrations from 50 




To determine the reproducibility of the assay using saliva samples and to confirm the 
previous colorimetric results, the second round of colorimetric RT-LAMP was performed, shown 
in Figure 16 below. Columns one through three contain the same control material as previously 
mentioned with IDTE buffer as the no-template control, saliva negative for SARS-CoV-2 as the 
negative control, and 100 copies per reaction of gRNA as the positive control. Contrived samples 
used produced reactions with 175 copies to 300 copies of gRNA and analyzed in triplicate for 
each primer set. Similar to the first experiment using contrived samples, the assay's sensitivity 
was slightly impacted by using a more complex sample. As seen in the previous RT-LAMP 
assays, each primer set performs differently, with the envelope primer set having the best 
sensitivity. Based on the reproducibility, 200 copies per reaction can be considered the limit of 
detection for this study as 100% of the samples (18/18) generated a robust positive color change 
for all three primer sets in all reactions. 
 
Figure 16 Colorimetric RT-LAMP of SARS-CoV-2 Contrived Samples Limit of Detection 
confirmation. Colorimetric interpretation after incubation for 40 minutes at 65.0°C and inactivated at 
95.0°C for 5 minutes. Red font indicating limit of detection. Samples include IDTE buffer for non-
template control, saliva from SARS-CoV-2 negative donor for negative control, 200 copies of SARS-
CoV-2 gRNA as positive control, and contrived samples containing SARS-CoV-2 genomic RNA at 
concentrations from 50 copies – 250 copies reaction. Photographed using cell phone camera. 
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Restriction Digest Results 
 Purified SARS-CoV-2 Genomic RNA 
To confirm that the expected product was produced during the RT-LAMP reaction, a 
restriction digest is performed using amplicons generated from RT-LAMP F3 and B3 primers 
from Orf1ab, envelope, and nucleocapsid primer sets. An amplicon of known size was generated 
using a reverse transcribed template from the B3 LAMP primer as the input material in an RT-
PCR reaction. Nucleic acid was amplified with RT-LAMP using B3 from each primer set at a 
working stock concentration of 20 µM and processed using the standard incubation and 
inactivation steps. Next, RT-LAMP samples were used in an RT-PCR assay with 20 µM F3 and 
B3 primer mix and amplified using the standard PCR protocol with the annealing temperature at 
65°C. Table 6 below contains Ct-values of amplified samples from the RT-PCR experiment 
using the F3 and B3 LAMP primers. Below in figure 17 shows the RT-PCR amplification curves 
for each amplicon and their respective melt curves. Visually, the amplification curves show an 
efficient reaction with all Ct-values below 32, as seen in the top image. The bottom three images 
in figure 17 show the melt curves that indicate sufficient primer specificity, with one prominent 
peak indicating one product was produced, which was used in the restriction digest.    
 
Table 6 RT-PCR Data of Amplified SARS-CoV-2 Genomic RNA. RT-PCR amplification using 
Orf1ab, Envelope, and Nucleocapsid LAMP F3 and B3 Primers for purified SARS-CoV-2 genomic RNA. 
Primer set curve label and produced Ct-value.   
RT-PCR data of F3:B3 amplification of gRNA samples 
Primer set Curve label Ct-value 
Orf1ab A 26.21 
Envelope B 31.40 







Figure 17 RT-PCR Analysis of SARS-CoV-2 Genomic RNA. Top: RT-PCR amplification curves using 
F3 and B3 from Orf1ab (C), envelope (B), and nucleocapsid (A) LAMP primer set. Bottom: Melt curve 
analysis for nucleocapsid, envelope, and Orf1ab respectively.   
 
The amplicons generated using RT-PCR were used in a restriction digest using the 
respective enzymes Apo1-HF to digest Orf1ab amplicons, Hpal to digest envelope amplicons, 
and Ndel nucleocapsid amplicons, each enzyme making one cut. Following digestion and 
enzyme inactivation, pre-digest and post-digest samples were analyzed using a 3% agarose gel 




Figure 18 Restriction Digest Confirms Amplification of SARS-CoV-2 Purified Genomic RNA. Lane 
1 contains NEB ultra-low range DNA ladder. Pre-digest product RT-PCR product, post-digest product is 
RT-PCR product digested with respective enzyme. 3% agarose gel electrophoresis, run at 120 Volts.  
 
The expected pre-digest band size using Orf1ab F3 and B3 primers is 289 base pairs, and 
the expected post-digest products using Apol-HF is 104 base pairs and 185 base pairs in length, 
which matched the banding pattern achieved for both Orf1ab pre and post digest samples shown 
in figure 18. In the Orf1ab post-digest specifically was some residual pre-digest product 
remaining with a band at 289 base pairs. The expected pre-digest product size using the envelope 
F3 and B3 primers is 216 base pairs, and the expected post-digest product using Hpal result band 
sizes of 160 base pairs and 56 base pairs, which match the banding pattern achieved. In the post-
digest analysis, the 56 base pair fragments displayed poor resolution, which resulted in a faint 
band. Lastly, using the nucleocapsid F3 and B3 primers, the expected pre-digest size is 217 base 
pairs, and the post-digest with Ndel, the fragments would be 140 base pairs and 77 base pairs in 
length. The banding pattern produced matched the expected results. Like the envelope post-
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digest sample, the nucleocapsid post-digest sample 77 base pair products displayed a more 
inadequate resolution, resulting in a faint band. From the restriction digest results shown in table 
5, figure 17, and figure 18, it was determined that the LAMP F3 and B3 primers were specific to 
their intended regions based on the RT-PCR and restriction digest results. The RT-PCR analysis 
using the two LAMP primers produced a single amplicon indicated by the single peak in the melt 
curve analysis. Confirmation of the product size using a restriction digest produced the expected 
fragment lengths, indicating the specificity of the primers. 
 Contrived Samples 
Knowing the LAMP F3 and B3 primers are specific to their regions of the SARS-CoV-2 
genome, a restriction digest experiment was performed using contrived samples to determine the 
specificity of the primers in the presence of human genomic DNA. Reverse transcription was 
performed first using LAMP B3 amplification, followed by amplified using F3 and B3 primers 
from each primer pair in RT-PCR. Below in table 7 and figure 19 below contains the RT-PCR 
data produced when using contrived samples analyzed in duplicate. The top graph in figure 18 
shows the amplification curves for all three primers sets; using visual evaluation, the 
nucleocapsid showed the best reaction efficiency, followed by Orf1ab, and the envelope showed 
minimal to no amplification. The bottom three graphs in figure 19 show the melt curve analysis 
for each primer set, with prevalent non-specific binding of primer characterized by the multiple 





Table 7 RT-PCR Data of Amplified SARS-CoV-2 in Contrived Samples. RT-PCR amplification 
using Orf1ab, Envelope, and Nucleocapsid LAMP F3 and B3 Primers for contrived samples. Primer set 
curve label and produced Ct-value.   
RT-PCR data of F3:B3 amplification of contrived samples 
Primer set Curve label Ct-value 
Orf1ab A 33.84 
Orf1ab B 34.41 
Envelope C 42.65 
Envelope D - 
Nucleocapsid E 26.62 





Figure 19 RT-PCR Analysis of Amplified SARS-CoV-2 Nucleic Acid from Contrived Samples. Top: 
RT-PCR amplification curves using F3 and B3 from Orf1ab (A, B), envelope (C, D), and nucleocapsid 
(E, F) LAMP primer sets. Bottom: Melt curve analysis for Orf1ab, envelope, and nucleocapsid 
respectively.   
 
The material produced in the RT-PCR reaction was used in the restriction digest using the 
same respective enzymes for each primer set as in the previous experiment. Following digestion 
and enzyme inactivation, pre-digest and post-digest samples were analyzed using a 3% agarose 




Figure 20 Restriction Digest of Amplified SARS-CoV-2 Nucleic Acid from Contrived Samples. Lane 
1 contains NEB 1kb DNA ladder. Pre-digest product RT-PCR product, post-digest product is RT-PCR 
product digested with respective enzyme. 3% agarose gel electrophoresis, run at 120 Volts. 
 
The generated results from table 7, figure 19, and figure 20 show that when contrived 
samples are used, there was significant interference of the human genomic DNA. Interference 
from human genomic DNA was first identified in the RT-PCR data, specifically in the melt 
curve analysis. In contrast to using purified SARS-CoV-2 gRNA, the contrived samples 
produced curves with multiple peaks or curves, which indicate that multiple products are being 
generated. The significant increase also saw this interference in the number of bands seen in the 
gel lanes for primers Orf1ab and nucleocapsid resulting from digested human genomic DNA. 
Using this experimental design, the envelope primer set yielded no detectable nucleic acid on the 
agarose gel when used with contrived samples. These two observed influences of saliva would 
inhibit any reliable restriction digest analysis, but using purified genomic RNA increased the 
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confidence in the specificity of the primers despite the interference of the human genomic DNA 
in contrived samples.   
RT-LAMP Turbidimetric Results 
Evidence showing that the colorimetric LAMP end-point analysis combined with the 
three independent studied primer sets can reliably and specifically detect 200 copies of SARS-
CoV-2 genomic RNA in a contrived sample; next experiments were performed to evaluate how 
the Turbidimetric LAMP end-point analysis performs for SARS-CoV-2 detection in saliva. 
Figure 21 below shows the use of Orf1ab, envelope, and nucleocapsid primer sets for SARS-
CoV-2 gRNA detection of contrived saliva samples. Samples used in the turbidimetric assay 
include a negative control consisting of saliva from a SARS-CoV-2 negative donor and a 
positive control consisting of 400 copies per reaction of SARS-CoV-2 genomic RNA. Contrived 
samples contained a range of SARS-CoV-2 gRNA producing 50 copies to 1000 copies per 
reaction, assayed in triplicate. Using an Eiken LA-500 Real-time Turbidimeter and the pre-
programmed SARS setting, amplification was performed for 45 minutes, and post-analysis using 




Figure 21 Turbidimetric LAMP Detection of SARS-CoV-2 in Contrived Samples. Lane 1 contains 
NEB 1kb DNA ladder, lane 2 contains negative control (SARS-CoV-2 negative saliva), and lane 3 
contains the positive control (400 copies SARS-CoV-2 genomic RNA). Tubes photographed using cell 
phone camera. 3% agarose gel electrophoresis, run at 120 Volts. 
 
Amplification was determined by the presence of any characteristic ladder banding 
pattern in the gel, and the limit of detection was characterized by the lowest amount of nucleic 
acid, where all samples generated a positive result. Using this approach, the lowest SARS-CoV-2 
genomic RNA in a contrived sample that was positive in all primer and triplicates using the 
turbidimetric end-point analysis was approximately 750 copies per reaction. To assess the 
reproducibility and confirm the previous results, another turbidimetric RT-LAMP using 
contrived samples was performed on a range of contrived samples producing 200 to 750 copies 




Figure 22 Turbidimetric RT-LAMP Detection of SARS-CoV-2 in Contrived Samples Confirmation. 
Lane 1 contains NEB 1kb DNA ladder, lane 2 contains negative control (SARS-CoV-2 negative saliva), 
and lane 3 contains the positive control (400 copies SARS-CoV-2 genomic RNA). Tubes photographed 
using cell phone camera. 3% agarose gel electrophoresis, run at 120 Volts. 
 
Figure 21 and figure 22 confirm that 750 copies per reaction was the limit of detection for 
using this end-point analysis. Again, determined by the presence of a ladder banding pattern in 
each triplicate in each primer, 100% of samples (18/18) tested in triplicate show positive 
amplification for reactions with 750 copies of SARS-CoV-2 genomic RNA. Compared to the 
experimentally determined LOD of the colorimetric end-point analysis (200 copies per reaction), 
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the turbidimetric analysis had a somewhat decreased analytical sensitivity at 750 copies per 
reaction. 
Surveillance Study 
A surveillance study was conducted with IRB approval, testing 47 saliva samples from 47 
donors who met the inclusion criteria. As a means of releasing intracellular SARS-CoV-2 
genomic RNA and minimize RNA degradation via RNases (naturally occurring enzymes that 
digest RNA), saliva samples were treated using proteinase K (PK) treatment, by incubating 100 
µL of saliva and 13 µL of PK for 1 minute at 37°C followed by PK inactivation at 95°C for 5 
minutes using a Thermomixer. Next, 5 µL of the treated saliva was then added to 20 µL of 
complete RT-LAMP master mix and incubated in a 65°C water bath for 40 minutes followed by 
inactivation at 95°C for 5 minutes. Color change interpretation was performed after samples have 
cooled to room temperature after the inactivation step. Figure 23 below shows the colorimetric 
results at 10-minute intervals from donors 1-27 using the nucleocapsid primer set. Below each 
reaction tube is the result interpretation with (-) indicating no amplification or a negative result 
and a red (+) for amplification or a positive result. A positive result was determined by 
comparing the color change to the positive control and the robustness of the color change itself. 
The no-template control used is a sterile IDTE buffer. The negative control is saliva from a 
SARS-CoV-2 negative donor. The positive control is saliva from a positive SARS-CoV-2 donor, 
and the release control is negative donor saliva spiked with inactivated SARS-CoV-2 viral 
particles (ATCC number: VR-1986HK lot: 70036071). Out of 27 saliva donors, three were 
determined to have a positive colorimetric color change indicating the presence of potential 




Figure 23 Donor Saliva Samples 001-027 Tested Using Colorimetric RT-LAMP for SARS-CoV-2 
Nucleocapsid Gene. Donor saliva samples 001-027 treated using saliva treatment protocol and analyzed 
using RT-LAMP. No template control is IDTE buffer, negative control is saliva from SARS-CoV-2 
negative donor, positive control is saliva from a SARS-CoV-2 positive donor, and the (R.C.) treatment 
control is inactivated SARS-CoV-2 viral particles spiked in saliva. Photographed using cell phone 
camera. 
Following the same protocol, saliva from donors 028-035 were tested using RT-LAMP 
using the nucleocapsid, envelope, and Orf1ab primer sets. The colorimetric results are shown 
below in figure 24, showing one out of eight donor samples generating a positive color change 
indicating the potential presence of SARS-CoV-2 genetic material. Samples display some 




Figure 24 Donor Saliva Samples 028-035 Tested using Colorimetric RT-LAMP for SARS-CoV-2 
Orf1ab, Envelope, and Nucleocapsid Genes. Donor saliva samples 028-035 treated using saliva 
treatment protocol and analyzed using RT-LAMP. No template control is IDTE buffer, negative control is 
saliva from SARS-CoV-2 negative donor, positive control is saliva from a SARS-CoV-2 positive donor, 
and the (R.C.) treatment control is inactivated SARS-CoV-2 viral particles spiked in saliva. Photographed 
using cell phone camera. 
 
Following the same protocol, saliva from donors 036-047 were tested using RT-LAMP 
using the nucleocapsid, envelope, and Orf1ab primer sets. The colorimetric results are shown 
below in figure 25, showing one out of 12 donor samples generating a positive color change 
indicating the presence of potential SARS-CoV-2 genetic material. Samples display some 
moderate evaporation as images were taken after storage. Out of the 47 donor-treated saliva 
samples tested using the RT-LAMP assay, five generated a positive color change giving a 
positive test rate of 10%. The conclusion of this study was that this methodology was 
successfully used for asymptomatic SARS-CoV-2 detection in donor saliva samples, and that the 






Figure 25 Donor Saliva Samples 036-047 Tested using Colorimetric RT-LAMP for SARS-CoV-2 
Orf1ab, Envelope, and Nucleocapsid Genes. Donor saliva samples 036-047 treated using saliva 
treatment protocol and analyzed using RT-LAMP. No template control is IDTE buffer, negative control is 
saliva from SARS-CoV-2 negative donor, positive control is saliva from a SARS-CoV-2 positive donor, 
and the (R.C.) treatment control is inactivated SARS-CoV-2 viral particles spiked in saliva. Photographed 

















This study is the first attempt at a workflow designed explicitly for asymptomatic SARS-
CoV-2 monitoring using a less invasive saliva sample for analysis employing RT-LAMP for 
screening a campus population. The cumulative results show that the colorimetric RT-LAMP 
design offers a high throughput workflow while providing the analytical sensitivity and 
specificity required of a molecular assay and highlights the shortcomings of the emergency 
released CDC N1 RT-PCR assay SARS-CoV-2 testing using saliva samples. RT-PCR 
optimization attempts yielded no improvements in the assay's performance with changes to 
primer and probe concentration, annealing temperature, or the use of the PCR kit enhancer. 
Overall, these findings parallel many of the scientific community's complaints of poor analytical 
performance when using the CDC N1 RT-PCR assay for SARS-CoV-2 testing, as previously 
mentioned. The gathered experimental evidence suggests that the design of the CDC N1 primers 
and probe is not optimal for use with saliva samples and requires modifications to enhance the 
assay's performance.  
With the poor performance, the assay could detect higher concentrations of SARS-CoV-2 
nucleic acid around 500 copies in contrived samples but failed to detect samples having a lower 
concentration of 200 copies per reaction. The poor sensitivity of the assay can be attributed to the 
poor performance of the primers and probe as the reactions occur with poor efficiency, 
negatively affecting the detection capabilities of the assay. Again, the poor performance is 
indicated by the shape of the amplification curves not being sigmoidal, and the Ct-values and 
orientation of curves generated using different amounts of SARS-CoV-2 nucleic acid are not 
representative of the difference in concentrations. Similar to the contrived samples, using 
purified SARS-CoV-2 genomic RNA yielded results displaying poor reaction efficiencies despite 
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the absence of saliva and the use of the kit enhancer. The limit of detection becomes negatively 
impacted, but the detection limit narrows the inclusion of the population tested, as symptomatic 
populations would likely have higher viral loads compared to asymptomatic populations, which 
would potentially cause a drastic increase in false-negative results. Again, patient testing using 
the CDC N1 RT-PCR assay had the majority of testing a patient population who were mainly 
symptomatic to save testing resources. However, any asymptomatic, post-exposure testing or 
individuals early in the infection stage could receive false-negative results due to the assays' poor 
sensitivity.  
Another consideration is that the CDC N1 primer sequences are complementary to 
regions within the human genome when analyzed with NCBI BLAST (data not shown), which, 
when used in an RT-PCR reaction with SYBR Green 1 detection, has shown prominent non-
specific binding of the primers seen in the melt curve analysis. The CDC's attempt to curb this 
undesirable outcome was the addition of the Taqman probe, which would bind to its specific 
region within the borders of the PCR primers to increase the specificity of the detection. The 
evidence gathered in this study has shown the incorporation of the probe to allow only the 
detection of SARS-CoV-2 nucleic acid. However, due to the inefficiency of the primers and the 
non-specific amplification, the detection is negatively affected when using saliva samples.  
In contrast to the CDC N1 analysis, the colorimetric RT-LAMP assay demonstrated 
excellent utility for asymptomatic SARS-CoV-2 monitoring using saliva samples. Evidence 
presented throughout this study has shown the RT-LAMP design to be the superior methodology 
in sensitivity, specificity, and high throughput testing capabilities. The limit of detection for the 
CDC N1 RT-PCR assay is approximately 500-1,000 copies of RNA in a contrived sample, while 
RT-LAMP demonstrated a limit of detection at approximately 200 copies in a contrived sample. 
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The CDC N1 assay requires incorporating a Taqman probe to decrease the amount of non-
specific amplification detection of human genomic DNA due to the poor design of the primers, 
while the RT-LAMP primers show no non-specific amplification of human genomic DNA in a 
LAMP reaction. These findings of colorimetric RT-LAMPs superiority to RT-PCR in sensitivity 
show comparable results to previously published studies (30, 31), and the increase in the limit of 
detection shown in this study using contrived samples can be found in previously published data 
that also found saliva pre-treatment strategies enhancing RT-LAMPs performance (17).  
The RT-LAMP design outperforms RT-PCR in terms of sensitivity and specificity, targeting 
three distinct regions of the SARS-CoV-2 genome resulting in a high level of reproducibility at 
200 copies per reaction (18/18) using contrived samples. In addition, there is not any presence of 
non-specific amplification of the negative saliva controls from SARS-CoV-2 negative donors in 
the colorimetric and turbidimetric RT-LAMP applications.  
The confirmatory study supporting the assay's specificity is the restriction digest 
performed for both non-contrived and contrived samples. The approach to generating the input 
nucleic acid for the digest consisted of reverse transcription using the B3 primer only, followed 
by F3 and B3 amplification using RT-PCR. The F3 and B3 primers are used in the RT-PCR 
reaction because they flank the outer regions of the targeted sequence of the RT-LAMP primer 
set, generating a single product of a known size, which is required for this restriction digest 
experiment. A pre-digest and post-digest sample was analyzed using gel electrophoresis for each 
primer set, with each showing the expected pre-digest band size and at least one expected post-
digest band size with precise resolution. This suboptimal clarity is likely due to the difficulty of 
resolving small DNA fragments using gel electrophoresis resulting in faint bands as seen for the 
expected bands ≤ 100 base pairs. Achieving the expected pre-digest and post-digest nucleic acid 
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sequence lengths indicates that the primers bind specifically to their designed region within the 
SARS-CoV-2 genome using purified SARS-CoV-2 genomic RNA. When this same technique is 
applied using contrived samples, the results indicated significant human genomic DNA 
interference within the saliva matrix. Unlike the purified gRNA, the digest using contrived 
samples shows many bands per lane within the gel, indicating that human genomic DNA was 
also digested, inhibiting any analysis of primer specificity using this technique.  
In addition to RT-LAMP superiority over RT-PCR in sensitivity and specificity, the high 
throughput capabilities are also more ideal by taking advantage of two characteristics of a LAMP 
assay. LAMP can be used for many different sample types, such as purified nucleic acids and 
even crude nucleic acid extractants, making analysis more accessible, faster, and cheaper. In 
contrast, the RT-PCR assays suggest using purified nucleic acid samples, which increases the 
workload, turn-around time, and cost of a test. The second characteristic of LAMP allowing 
more excellent high throughput capabilities is that sample restriction is not based on the number 
of expensive thermocyclers as when using RT-PCR, but rather the space within hot water baths 
or heat blocks. This capability can allow for a much higher sample processing volume than what 
could be achieved using thermocyclers.  
Turbidimetric RT-LAMP is assessed for two purposes; the first used as an additional 
confirmatory assay utilizing all three RT-LAMP primer sets with input nucleic acid using 
contrived samples, and to determine which LAMP end-point analysis offers better usability 
colorimetric or turbidimetric. The real-time turbidimeter data output was inaccurate as samples 
with visible precipitation were not consistently detected using the analyzer; instead, samples 
were analyzed using agarose gel electrophoresis. Results from this confirmatory analysis indicate 
the RT-LAMP primers are specific to SARS-CoV-2 nucleic acid, but the RT-LAMP end-point 
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analysis change to turbidimetric detection negatively impacted the limit of detection. This 
supports the utility of the RT-LAMP primer sets and that the colorimetric end-point analysis is 
the superior end-point methodology.  
The need for a rapid and straightforward molecular assay for SARS-CoV-2 detection for 
use in a campus setting was in great need, and the utility of three already studied RT-LAMP 
primer sets gave the ability to begin immediate surveillance in mid-September in the height of 
the pandemic before optimization of the workflow could be performed. This screening 
comprised testing 47 saliva samples from 47 donors, primarily nursing students and RAs 
displaying no COVID19 symptoms using RT-LAMP, which can be seen in figures 22-25. From 
the brief study of 47 donor saliva samples, five generated a positive color change utilizing the 
nucleocapsid primer set, yielding a 10% positive test rate. In comparison to symptomatic 
individual testing reported by NMU of 0.6%, Marquette county of 2.0% in mid-September (4), 
and 10.0% for the state of Michigan in mid-September (4) under the assumption the majority are 
symptomatic.  
Despite the results showing the high prevalence of asymptomatic SARS-CoV-2 positive 
carriers, the University chose to halt any further testing using this well-studied workflow 
permanently. The shutdown of testing resulted from a shortage in supplies in the laboratory 
where confirmatory testing was completed, in which 0/5 donors who tested positive using the 
RT-LAMP workflow tested negative using a multiplexed RT-PCR assay. Unknown to University 
administration is that a multiplexed assay causes significant loss in sensitivity for each target 
tested for, which leads to higher rates of false-positive results. Unlike the RT-LAMP assay, with 
each reaction specific to a unique target allowing the assay to uphold its sensitivity and 
specificity, specificity can be another concern when using multiplexed assays. With the 
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optimization of the workflow completed, it is possible that the prevalence of SARS-CoV-2 could 
have been more accurately assessed if this workflow was employed for university surveillance 
and not abruptly shut down.  
RT-LAMPs usability is superior not only for campus surveillance, but this assay can have 
many other additional positive impacts in the context of this pandemic and future pandemics. 
Not only does LAMP sensitivity and specificity make this molecular technique ideal for SARS-
CoV-2 testing, but also the methods adaptability. This molecular technique can be easily 
modified to detect different viral variants or strains, such as the variants of SARS-CoV-2 that 
have emerged in different parts of the world, making testing difficult. This adaptability is also 
important when considering future pandemics as this methodology offers more sensitivity, 
specificity, and the inclusion of a broader range of sample types compared to the standard PCR 
method commonly used. In the context of this pandemic, the control of this pandemic and the 
number of resources and lives saved could have been significantly improved if a better-suited 
molecular technique was employed for testing, such as LAMP.  
This workflow is the first of its kind to utilize less invasive saliva samples in an RT-
LAMP assay to detect asymptomatic SARS-CoV-2 using saliva samples from a university 
population. This study found that the colorimetric RT-LAMP design is more user-friendly and 
has a faster turn-around time, and has superior analytical sensitivity and specificity over the CDC 
N1 RT-PCR assay. With successful optimization of the RT-LAMP workflow, a small 
surveillance study of primarily nursing students and RAs found a significantly higher SARS-
CoV-2 campus prevalence of 10% than the <1% reported by the University. Despite the evidence 
gathered in this study supporting the SARS-CoV-2 diagnostic capability of RT-LAMP, and the 
use of other well-known organizations utilizing this methodology, the campus surveillance 
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testing was shut down allowing undiagnosed asymptomatic SARS-CoV-2 carriers to continue in 
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